Prestige BioPharma Limited (KRX:950210)

South Korea · Delayed Price · Currency is KRW

5,640.00

-320.00 (-5.37%)

Oct 12, 2026, 3:30 PM KST

Prestige BioPharma Ratios and Metrics

Market cap in millions KRW. Fiscal year is July - June.

Millions KRW. Fiscal year is Jul - Jun.

Total Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct '26 Oct 9, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Market Capitalization	67,788	77,644	176,683	103,966	113,582	137,620
Market Cap Growth	-56.68%	-56.05%	69.94%	-8.47%	-17.47%	-65.30%
Enterprise Value	180,935	181,904	210,197	44,042	-6,736	-150,494
Last Close Price	5640.00	6460.00	14700.00	8650.00	9450.00	11450.00

Price Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct '26 Oct 9, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
PE Ratio	-	-	7.92	-	6.47	-
Forward PE	-	12.01	12.01	12.01	12.01	12.01
PS Ratio	2.60	2.98	12.33	150.88	701.81	-
PB Ratio	0.13	0.15	0.35	0.20	0.21	0.32
P/TBV Ratio	0.18	0.20	0.48	0.26	0.28	0.32

EV Ratios

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct '26 Oct 9, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
EV/Sales Ratio	6.94	6.98	14.67	63.92	-	-

Financial Efficiency

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct '26 Oct 9, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Debt / Equity Ratio	0.21	0.21	0.30	0.17	0.21	0.01
Debt / EBITDA Ratio	-	-	-	-	9.11	-
Net Debt / Equity Ratio	0.08	0.08	-0.05	-0.26	-0.34	-0.69
Net Debt / EBITDA Ratio	-0.67	-0.67	0.61	2.89	-14.65	2.52
Net Debt / FCF Ratio	-0.66	-0.66	0.29	1.95	1.71	2.92
Asset Turnover	0.04	0.04	0.02	0.00	0	-
Inventory Turnover	1.42	1.42	1.18	0.89	0.01	-
Quick Ratio	0.48	0.48	1.09	1.53	2.24	7.26
Current Ratio	0.75	0.75	1.27	1.72	2.31	7.46
Return on Equity (ROE)	-24.27%	-24.27%	0.81%	-10.38%	-0.59%	-42.08%
Return on Assets (ROA)	-7.87%	-7.87%	-5.71%	-5.35%	0.10%	-13.89%
Return on Capital Employed (ROCE)	-15.80%	-15.80%	-11.50%	-11.00%	0.20%	-26.80%

Yields

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct '26 Oct 9, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Earnings Yield	-134.98%	-117.84%	12.62%	-31.66%	15.47%	-153.65%
FCF Yield	-91.15%	-79.58%	-52.57%	-65.49%	-95.65%	-74.36%
Buyback Yield / Dilution	-	-	-0.22%	0.22%	-	-16.46%